Allergan CEO says the company is hunting for smaller acquisitions to boost growth after its $160 billion Pfizer merger fell through.
CEO Brent Saunders said in a Bloomberg tv interview, "With respect to M&A, we will be looking at more smaller-scale tuck-in deals that will support our therapeutic area leadership and innovation."
Allergan will have $20 billion to invest in growth and innovation after it sells its generic business to Teva.
Read the Bloomberg release